Ireland - English - HPRA (Health Products Regulatory Authority)

sol s.p.a. - nitrous oxide - medicinal gas, liquefied - 100 percent volume/volume - other general anesthetics; nitrous oxide

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 42977 - wound carbon dioxide diffusion set - a device to diffusely insufflate carbon dioxide (co2) into an open surgical wound to reduce the risk of air embolism. it has a hydrophobic diffusing tip, bacterial filter and tubing to allow connection to a regulated co2 source. it is a single use device.

Australia - English - Department of Health (Therapeutic Goods Administration)

fisher & paykel healthcare pty ltd - 42977 - wound carbon dioxide diffusion set - 1) for the distribution of humidified and heated co2 during open surgery in order to avoid dehydration and cooling of the operative wound. 2) for the prevention of air embolism in open-heart surgery.

Singapore - English - HSA (Health Sciences Authority)

gold lite pte ltd - general hospital - the powercube body+/diffusion+ is a pc-based ultrasonic system for measuring and analysing breath flow and volume. it is intended for use in hospital and clinic settings to measure and analyse lung function parameters in adult and paediatric over 5 years of age. the powercube body+/diffusion+ is indicated in the following situations: -to detect the presence or absence of pulmonary dysfunction -to determine the effect of lung disease -to screen individuals at risk for lung disease -to assess preoperative risk -to assess the potential effects or response to environmental or occupational exposure -to assess impairment and/or disability -to monitor the effects of therapy -to describe the progression of lung diseases -to monitor for adverse reactions to drugs with known pulmonary toxicity bodyplethysmography: -airway resistance -lung volume detection diffusion: -single breath diffusion -real time single breath diffusion

Australia - English - Department of Health (Therapeutic Goods Administration)

fisher & paykel healthcare pty ltd - 42977 - wound carbon dioxide diffusion set - for the insufflation of an open surgery wound with humidified and heated air during open orthopaedic surgery. to be operated by a theatre technician or healthcare provider with experience in the set-up of surgical equipment.

Australia - English - Department of Health (Therapeutic Goods Administration)

fisher & paykel healthcare pty ltd - 42977 - wound carbon dioxide diffusion set - to deliver warm, humidified carbon dioxide (co2)?into the surgical cavity during open surgery.

Singapore - English - HSA (Health Sciences Authority)

the binding site pte. ltd. - immunology - this kit is intended for measuring human immunoglobulin d (igd) in serum as an aid in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.